Blocking CTLA-4 inhibits Tregs, reactivates T cells suppressed within the TME, and accompanies an increase in IFN-γ production, thereby inducing PD-L1 expression in the TME and subsequently inhibiting T cell anti-tumor responses [367]. The gene discussed is IFNG; the disease is neoplasm.